Author's response to reviews

Title: Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.

Authors:

Nicolas Isambert (nisambert@cgfl.fr)
Pierre Fumoleau (pfumoleau@cgfl.fr)
Catherine Paul (catherine.paul@u-bourgogne.fr)
Christophe Ferrand (christophe.ferrand@efs.sante.fr)
Sylvie Zanetta (szanetta@cgfl.fr)
Jacques Bauer (Jacques.BAUER@viforpharma.com)
Kevin Ragot (kevinrex71@hotmail.com)
Gérard Lizard (gerard.lizard@u-bourgogne.fr)
Jean-Francois Jeannin (Jean-francois.Jeannin@u-bourgogne.fr)
Marc Bardou (Marc.Bardou@u-bourgogne.fr)

Version: 2 Date: 26 September 2012

Author's response to reviews: see over
Dijon, 26 September 2012

Dear Editor,

You will find enclosed for submission in your journal an article entitled “Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors”.

Following this phase 1 study in which the lipid A analog OM-174 is well tolerated, a second phase I assay is in progress to test Folfox plus OM-174. If this treatment is well tolerated as it is expected (Folfox is one of the current standard treatment of advanced stage colon cancer), a study of the incremental efficacy of the combination with respect to Folfox alone will be carried out.

As you have requested, the trial registration number was included in the abstract of the manuscript.

The authors declare that they have no competing interest.

Hopefully this article will be accepted for publication, please believe in my deepest respect.

Docteur Nicolas ISAMBERT